All In Biotech

Free tool

FAERS Monitor: Delstrigo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210807 or its brand name (Delstrigo, Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate). Reports on generic versions are filed under their own applications.

Reports

313

Serious

259

83% of reports

Hospitalization

71

Death reported

24

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death20
  • nausea20
  • weight increased18
  • pain17
  • anxiety14
  • fatigue13
  • no adverse event13
  • pathogen resistance13
  • depression12
  • headache12
  • product dose omission issue12
  • diarrhoea11
  • virologic failure11
  • emotional distress10
  • weight decreased10

Reports by year received

View as table
YearReports
20081
20196
202025
202133
202232
202367
202464
202554
202631

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,846 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
virologic failureSignal11137.777.01,357
pathogen resistanceSignal1396.056.31,128
emotional distressSignal105.63.033
weight increasedSignal185.43.461
no adverse eventSignal134.82.836
depressionSignal123.52.020
anxietySignal143.32.021
product dose omission issueSignal122.71.612
weight decreasedSignal102.41.37
pain171.91.26
nausea201.71.15
death201.61.04
headache121.30.71
diarrhoea111.10.60
fatigue131.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.